[Form 4] Rapport Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Ceesay Abraham, who is listed as both Chief Executive Officer and a director of Rapport Therapeutics, Inc. (RAPP), reported multiple dispositions of the company’s common stock on 09/17/2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. The Form 4 lists four disposition entries: 39,435 shares at a weighted-average price of $26.299, 1,400 shares at $26.8745, 34,885 shares at $26.3019 and 700 shares at $27.0429. The filing shows resulting beneficial ownership figures on each line, including direct holdings of 585,412 and 586,812 shares on certain lines and indirect holdings held by the Dorothy Ceesay Irrevocable Trust and the Ceesay Family Irrevocable Trust (listed as 46,844 I, 46,144 I and 81,729 I). Explanatory notes disclose price ranges for the multiple transactions and that the reporting person disclaims beneficial ownership of trust-held shares except to the extent of any pecuniary interest.

Insights

Financial Analyst

TL;DR: Routine, pre-arranged insider dispositions under a 10b5-1 plan; transparent weighted-average pricing and updated beneficial ownership reported.

The reported transactions are sales executed under a Rule 10b5-1 plan adopted 12/12/2024, which signals these were pre-arranged dispositions rather than opportunistic market trades. The Form 4 provides weighted-average prices and ranges for the multiple executions, improving transparency on execution pricing. The filing updates both direct and indirect beneficial ownership amounts, including trust holdings. For investors, this is a clear disclosure of insider selling but contains no statements about company performance or changes to executive roles.

Corporate Governance Expert

TL;DR: Proper procedural disclosure of insider sales with trust separations noted; no governance or control changes reported.

The report appropriately identifies the reporting person’s roles and provides explanatory footnotes disclosing the 10b5-1 plan and the nature of trust-held shares, including disclaimers of beneficial ownership for trust assets. There are no indications in this filing of any change in executive or board status, nor any related-party transactions beyond routine trust holdings. The filing meets Section 16 reporting requirements for insider transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Ceesay Abraham

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/17/2025		S(1)		39,435	D	$26.299(2)	586,812	D
Common Stock	09/17/2025		S(1)		1,400	D	$26.8745(3)	585,412	D
Common Stock	09/17/2025		S(1)		34,885	D	$26.3019(4)	46,844	I	By Dorothy Ceesay Irrevocable Trust(5)
Common Stock	09/17/2025		S(1)		700	D	$27.0429(6)	46,144	I	By Dorothy Ceesay Irrevocable Trust(5)
Common Stock								81,729	I	By Ceesay Family Irrevocable Trust(7)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.74 to $27.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.78 to $26.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

5. Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.02 to $27.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

7. Shares held by The Ceesay Family Irrevocable Trust u/t/d March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

	/s/ Troy Ignelzi, Attorney-in-Fact	09/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.